Latest filings (excl ownership)
25-NSE
Exchange delisting
8 Sep 23
8-K
Entry into a Material Definitive Agreement
18 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Jun 23
8-K
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
30 May 23
8-K
Other Events
22 May 23
PRE 14A
Preliminary proxy
19 May 23
8-K
Entry into a Material Definitive Agreement
19 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
15 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
8-K
Entry into a Material Definitive Agreement
27 Apr 23
8-K
Entry into a Material Definitive Agreement
6 Apr 23
8-K
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding its GIP Antagonist NM-136 for Obesity
5 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
8-K
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
28 Mar 23
8-K
9 Meters Biopharma Announces $5 Million Registered Direct Offering
15 Mar 23
424B5
Prospectus supplement for primary offering
15 Mar 23
8-K
Other Events
13 Mar 23
8-K
Other Events
13 Mar 23
8-K
Entry into a Material Definitive Agreement
13 Jan 23
8-K
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide
29 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
8 Nov 22
8-K
Other Events
1 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
21 Oct 22
8-K
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
17 Oct 22
8-K
Entry into a Material Definitive Agreement
6 Oct 22
DEFA14A
Additional proxy soliciting materials
29 Sep 22
8-K
Other Events
29 Sep 22
8-K
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
26 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
15 Aug 22
8-K
Other Events
10 Aug 22
EFFECT
Notice of effectiveness
5 Aug 22
424B3
Prospectus supplement
4 Aug 22
DEF 14A
Definitive proxy
2 Aug 22
CORRESP
Correspondence with SEC
2 Aug 22
UPLOAD
Letter from SEC
1 Aug 22
S-3
Shelf registration
28 Jul 22
PRE 14A
Preliminary proxy
22 Jul 22
Latest ownership filings
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
144
Notice of proposed sale of securities
21 Jul 23
144
Notice of proposed sale of securities
19 Jul 23
144
Notice of proposed sale of securities
21 Apr 23
4
Bethany Sensenig
21 Apr 23
4
Mark A Sirgo
31 Mar 23
4
YEHUDA MICHAEL RICE
31 Mar 23
4
LORIN K JOHNSON
31 Mar 23
4
Michael T. Constantino
31 Mar 23
4
Samantha Ventimiglia
31 Mar 23
4
Bethany Sensenig
29 Mar 23
4
John Temperato
29 Mar 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
4/A
Mark A Sirgo
22 Jul 22
SC 13G
BlackRock Inc.
8 Jul 22
4
John Temperato
8 Jul 22
4
Mark A Sirgo
6 Jul 22
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
1 Jul 22
4
Mark A Sirgo
23 Jun 22
4
Samantha Ventimiglia
23 Jun 22
4
YEHUDA MICHAEL RICE
23 Jun 22
4
LORIN K JOHNSON
23 Jun 22
4
Michael T. Constantino
23 Jun 22
4
Michael T. Constantino
24 May 22
4
John Temperato
19 May 22
4
Mark A Sirgo
19 May 22
4/A
Michael T. Constantino
21 Mar 22
4
Mark A Sirgo
7 Mar 22
4
John Temperato
4 Mar 22
4
John Temperato
23 Feb 22
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
10 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22
4
Bethany Sensenig
18 Jan 22
3
Bethany Sensenig
18 Jan 22
4
Mark A Sirgo
3 Dec 21
4
Mark A Sirgo
22 Nov 21
4
John Temperato
19 Nov 21
4
Samantha Ventimiglia
4 Oct 21
3
Samantha Ventimiglia
4 Oct 21
4
Edward J Sitar
15 Sep 21